Exelixis
| Formerly | Exelixis Pharmaceuticals, Inc. (1994-2000) |
|---|---|
| Company type | Public |
| Industry | Biotechnology |
| Founded | November 1994 |
| Headquarters | Alameda, California, U.S. |
Key people | Stelios Papadopoulos, Ph.D. (chairman) Michael M. Morrissey, Ph.D. (president & CEO) |
| Revenue | US$ 1.435 Billion (2021) |
| US$ 0.287 Billion (2021) | |
| US$ 0.231 Billion (2021) | |
| Total assets | US$ 2.61 Billion (2021) |
| Total equity | US$ 2.211 Billion (2021) |
Number of employees | 954 (2021) |
| Website | exelixis |
| Footnotes / references | |
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.